The cell therapy industry is actively working to simplify and close processes to optimize manufacturing, reduce costs, and increase speeds of getting treatments to patients. While viral gene delivery has been in use for quite some time, nonviral delivery methods are attractive because of their reduced cytotoxicity, immunogenicity, and mutagenicity compared to viral vectors. Electroporation is particularly interesting as an alternative to viral delivery because of its simplicity of use and ease of large-scale production.
In this application note, learn about flexible, modular systems that can be easily adapted into existing workflows and enable closed manufacturing for the wash and concentration of cells and nonviral delivery of genetic material.
Download now and discover:
How the Gibco™ CTS™ Rotea™ Counterflow Centrifugation System and the Gibco™ CTS™ Xenon™ Electroporation System can help reduce risk, time and complexity in cell therapy manufacturing
How the CTS™ Rotea™ and CTS™ Xenon™ systems work together
Key aspects of working toward optimization and a standardization of cell therapy manufacturing workflows